Navigation Links
Haemacure Restructures - Seeks Financing or Sale of the Company
Date:2/13/2009

HAE:TSX

MONTREAL, Feb. 13 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE) announces that it has implemented cost-cutting measures in order to preserve cash. At the same time, the Company will continue to seek financing and will initiate a process intended to lead to a sale or merger of the Company.

Haemacure has been seeking financing since the third quarter of 2008. Several parties have expressed interest in an equity financing; however, this interest has not materialized into a viable financing. In light of the state of the financial markets, Haemacure believes that without operational changes its cash reserves will be exhausted before equity financing is completed, given Haemacure's operational burn rate and its previously-announced objective of getting into the clinic by mid-2009.

    Cost-Cutting Measures

    Haemacure has implemented the following measures, effective today:

    - 12 of Haemacure's 18 employees have been placed on leave in Montreal
      and Sarasota, Florida;
    - All major consulting agreements have been suspended;
    - Joseph Galli, Chairman & CEO, and Marc Paquin, President, will both
      continue to work with the Company for nominal compensation; and
    - The Company is undertaking measures with suppliers to restructure its
      obligations to them.

These restructuring measures provide the Company with a window of approximately 90 days in which to either arrange a bridge loan, obtain new financing, or to sell or merge the Company. As a result of these restructuring measures, and unless new financing is obtained, the Company will not commence the pivotal phase II/III clinical trials for its lead product candidate, an all-human fibrin sealant, as planned in mid-2009. However, the Company will continue, to the extent possible, with the preparation for these trials so that should funds become available the trials could commence without undue delay. A core team of manufacturing, quality and regulatory affairs and technical employees remains to preserve assets and support a potential sale or merger of the Company.

    Major Assets

    Haemacure's major assets are:

    - an operational state-of-the-art, cGMP-designed manufacturing facility
      in Sarasota, Florida for the production of fibrinogen and thrombin;
    - intellectual property allowing for low-cost and high-yield production
      of fibrinogen and thrombin;
    - an open IND with the U.S. Food and Drug Administration (FDA) pertaining
      to its all-human fibrin sealant which, assuming funding, would enter
      pivotal phase II/III clinical trials this summer; and
    - positive preclinical results on the use of its fibrin sealant for the
      prevention of the formation of postsurgical adhesion and for skin graft
      fixation for burn injuries.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development is focussed on the use of fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medecine, skin graft fixation for burn injuries, and wound healing. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure is headquartered in Montreal, Canada and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE Haemacure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
2. Haemacure Announces Fiscal 2008 Results
3. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
4. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
5. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
6. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
7. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
8. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
9. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
10. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
11. Haemacure Reports on Financing Progress and Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology: